Report Code: 11739 | Available Format: PDF | Pages: 370
Embolotherapy Market Research Report: By Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological and Nephrological Disorders, Gastrointestinal Disorders), End-User (Hospitals and Clinics, Ambulatory Surgical Centers) - Global Industry Analysis and Demand Forecast to 2030
- Report Code: 11739
- Available Format: PDF
- Pages: 370
- Report Description
- Table of Contents
- Market Segmentation
- Request Free Sample
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Embolic agents
4.1.1.1.1 Microspheres
4.1.1.1.2 Embolic coils
4.1.1.1.3 Liquid embolic agents
4.1.1.1.4 Embolic plug systems
4.1.1.1.5 Detachable balloons
4.1.1.2 Support devices
4.1.1.2.1 Microcatheters
4.1.1.2.2 Guidewires
4.1.2 By Procedure
4.1.2.1 TAE
4.1.2.2 TARE/SIRT
4.1.2.3 TACE
4.1.3 By Indication
4.1.3.1 Cancer
4.1.3.1.1 Kidney
4.1.3.1.2 Liver
4.1.3.1.3 Others
4.1.3.2 Peripheral vascular diseases
4.1.3.3 Neurological diseases
4.1.3.3.1 Cerebral aneurysm
4.1.3.3.2 Arteriovenous malformations & fistulas
4.1.3.4 Urological and nephrological disorders
4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
4.1.4.1 Hospitals & clinics
4.1.4.2 ASCs
4.1.4.3 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.2 Drivers
4.2.2.1 Growing patient pool
4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.3 Growing medical tourism sector
4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.5 Growing preference for MISs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Product recalls
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of liquid embolic agents
4.2.4.2 Untapped market in developing economies
4.3 Porter’s Five Forces Analysis
4.4 Regulatory Framework Analysis
4.4.1 U.S.
4.4.2 Europe
4.4.3 APAC
4.4.4 LATAM
4.4.5 MEA
Chapter 5. Global Market Size and Forecast
5.1 Global Market Size and Forecast
5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
5.3 By Procedure
5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
6.2 By Procedure
6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
6.4 By End User
6.5 By Country
6.5.1 U.S. Market Size and Forecast
6.5.1.1 By product
6.5.1.1.1 Embolic agents market, by type
6.5.1.1.2 Embolotherapy support devices market, by type
6.5.1.2 By procedure
6.5.1.3 By indication
6.5.1.3.1 Embolotherapy market for cancer, by type
6.5.1.3.2 Embolotherapy market for neurological diseases, by type
6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
6.5.2.1 By product
6.5.2.1.1 Embolic agents market, by type
6.5.2.1.2 Embolotherapy support devices market, by type
6.5.2.2 By procedure
6.5.2.3 By indication
6.5.2.3.1 Embolotherapy market for cancer, by type
6.5.2.3.2 Embolotherapy market for neurological diseases, by type
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 Germany Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 France Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
7.5.3.1 By product
7.5.3.1.1 Embolic agents market, by type
7.5.3.1.2 Embolotherapy support devices market, by type
7.5.3.2 By procedure
7.5.3.3 By indication
7.5.3.3.1 Embolotherapy market for cancer, by type
7.5.3.3.2 Embolotherapy market for neurological diseases, by type
7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
7.5.4.1 By product
7.5.4.1.1 Embolic agents market, by type
7.5.4.1.2 Embolotherapy support devices market, by type
7.5.4.2 By procedure
7.5.4.3 By indication
7.5.4.3.1 Embolotherapy market for cancer, by type
7.5.4.3.2 Embolotherapy market for neurological diseases, by type
7.5.4.4 By end user
7.5.5 Spain Market Size and Forecast
7.5.5.1 By product
7.5.5.1.1 Embolic agents market, by type
7.5.5.1.2 Embolotherapy support devices market, by type
7.5.5.2 By procedure
7.5.5.3 By indication
7.5.5.3.1 Embolotherapy market for cancer, by type
7.5.5.3.2 Embolotherapy market for neurological diseases, by type
7.5.5.4 By end user
Chapter 8. APAC Market Size and Forecast
8.1 By Product
8.1.1 Embolic Agents Market, by Type
8.1.2 Embolotherapy Support Devices Market, by Type
8.2 By Procedure
8.3 By Indication
8.3.1 Embolotherapy Market for Cancer, by Type
8.3.2 Embolotherapy Market for Neurological Diseases, by Type
8.4 By End User
8.5 By Country
8.5.1 China Market Size and Forecast
8.5.1.1 By product
8.5.1.1.1 Embolic agents market, by type
8.5.1.1.2 Embolotherapy support devices market, by type
8.5.1.2 By procedure
8.5.1.3 By indication
8.5.1.3.1 Embolotherapy market for cancer, by type
8.5.1.3.2 Embolotherapy market for neurological diseases, by type
8.5.1.4 By end user
8.5.2 Japan Market Size and Forecast
8.5.2.1 By product
8.5.2.1.1 Embolic agents market, by type
8.5.2.1.2 Embolotherapy support devices market, by type
8.5.2.2 By procedure
8.5.2.3 By indication
8.5.2.3.1 Embolotherapy market for cancer, by type
8.5.2.3.2 Embolotherapy market for neurological diseases, by type
8.5.2.4 By end user
8.5.3 India Market Size and Forecast
8.5.3.1 By product
8.5.3.1.1 Embolic agents market, by type
8.5.3.1.2 Embolotherapy support devices market, by type
8.5.3.2 By procedure
8.5.3.3 By indication
8.5.3.3.1 Embolotherapy market for cancer, by type
8.5.3.3.2 Embolotherapy market for neurological diseases, by type
8.5.3.4 By end user
8.5.4 South Korea Market Size and Forecast
8.5.4.1 By product
8.5.4.1.1 Embolic agents market, by type
8.5.4.1.2 Embolotherapy support devices market, by type
8.5.4.2 By procedure
8.5.4.3 By indication
8.5.4.3.1 Embolotherapy market for cancer, by type
8.5.4.3.2 Embolotherapy market for neurological diseases, by type
8.5.4.4 By end user
8.5.5 Singapore Market Size and Forecast
8.5.5.1 By product
8.5.5.1.1 Embolic agents market, by type
8.5.5.1.2 Embolotherapy support devices market, by type
8.5.5.2 By procedure
8.5.5.3 By indication
8.5.5.3.1 Embolotherapy market for cancer, by type
8.5.5.3.2 Embolotherapy market for neurological diseases, by type
8.5.5.4 By end user
Chapter 9. LATAM Market Size and Forecast
9.1 By Product
9.1.1 Embolic Agents Market, by Type
9.1.2 Embolotherapy Support Devices Market, by Type
9.2 By Procedure
9.3 By Indication
9.3.1 Embolotherapy Market for Cancer, by Type
9.3.2 Embolotherapy Market for Neurological Diseases, by Type
9.4 By End User
9.5 By Country
9.5.1 Brazil Market Size and Forecast
9.5.1.1 By product
9.5.1.1.1 Embolic agents market, by type
9.5.1.1.2 Embolotherapy support devices market, by type
9.5.1.2 By procedure
9.5.1.3 By indication
9.5.1.3.1 Embolotherapy market for cancer, by type
9.5.1.3.2 Embolotherapy market for neurological diseases, by type
9.5.1.4 By end user
9.5.2 Mexico Market Size and Forecast
9.5.2.1 By product
9.5.2.1.1 Embolic agents market, by type
9.5.2.1.2 Embolotherapy support devices market, by type
9.5.2.2 By procedure
9.5.2.3 By indication
9.5.2.3.1 Embolotherapy market for cancer, by type
9.5.2.3.2 Embolotherapy market for neurological diseases, by type
9.5.2.4 By end user
Chapter 10. MEA Market Size and Forecast
10.1 By Product
10.1.1 Embolic Agents Market, by Type
10.1.2 Embolotherapy Support Devices Market, by Type
10.2 By Procedure
10.3 By Indication
10.3.1 Embolotherapy Market for Cancer, by Type
10.3.2 Embolotherapy Market for Neurological Diseases, by Type
10.4 By End User
10.5 By Country
10.5.1 Saudi Arabia Market Size and Forecast
10.5.1.1 By product
10.5.1.1.1 Embolic agents market, by type
10.5.1.1.2 Embolotherapy support devices market, by type
10.5.1.2 By procedure
10.5.1.3 By indication
10.5.1.3.1 Embolotherapy market for cancer, by type
10.5.1.3.2 Embolotherapy market for neurological diseases, by type
10.5.1.4 By end user
10.5.2 South Africa Market Size and Forecast
10.5.2.1 By product
10.5.2.1.1 Embolic agents market, by type
10.5.2.1.2 Embolotherapy support devices market, by type
10.5.2.2 By procedure
10.5.2.3 By indication
10.5.2.3.1 Embolotherapy market for cancer, by type
10.5.2.3.2 Embolotherapy market for neurological diseases, by type
10.5.2.4 By end user
Chapter 11. Competitive Landscape
11.1 List of Other Players
11.2 Strategic Developments of Key Players
11.2.1 Product Launches & Approvals
11.2.2 Collaborations
11.2.3 Acquisitions
11.2.4 Expansions
Chapter 12. Company Profiles
12.1 Stryker Corporation
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2 Sirtex Medical Limited
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.3 Key Financial Summary
12.3 Merit Medical Systems Inc.
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Meril Life Sciences Pvt. Ltd.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.5 Acandis GmbH
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.6 Terumo Corporation
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Medtronic plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Kaneka Corporation
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 Johnson & Johnson
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
12.10 Boston Scientific Corporation
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
12.11 Abbott Laboratories
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
12.12 Guerbet
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
12.13 BALT EXTRUSION SAS
12.13.1 Business Overview
12.13.2 Product and Service Offerings
Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 REGULATORY AND APPROVAL BODIES FOR MEDICAL DEVICES IN LATAM COUNTRIES
TABLE 5 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 6 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 7 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 8 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 9 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 10 GLOBAL EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 11 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 12 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 13 GLOBAL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 14 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 15 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 16 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 17 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 18 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 19 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 20 GLOBAL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 21 GLOBAL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 22 GLOBAL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 23 GLOBAL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 24 GLOBAL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 25 GLOBAL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 26 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 27 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 28 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 29 GLOBAL EMBOLOTHERAPY MARKET, BY REGION, $M (2019–2024)
TABLE 30 GLOBAL EMBOLOTHERAPY MARKET, BY REGION, $M (2025–2030)
TABLE 31 GLOBAL EMBOLOTHERAPY MARKET, BY REGION, $M (2025–2030)
TABLE 32 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 33 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 34 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 35 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 36 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 37 NORTH AMERICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 38 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 39 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 40 NORTH AMERICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 41 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 42 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 43 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 44 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 45 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 46 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 47 NORTH AMERICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 48 NORTH AMERICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 49 NORTH AMERICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 50 NORTH AMERICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 51 NORTH AMERICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 52 NORTH AMERICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 53 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 54 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 55 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 56 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)
TABLE 57 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 58 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 59 U.S. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 60 U.S. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 61 U.S. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 62 U.S. EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 63 U.S. EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 64 U.S. EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 65 U.S. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 66 U.S. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 67 U.S. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 68 U.S. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 69 U.S. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 70 U.S. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 71 U.S. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 72 U.S. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 73 U.S. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 74 U.S. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 75 U.S. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 76 U.S. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 77 U.S. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 78 U.S. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 79 U.S. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 80 U.S. EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 81 U.S. EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 82 U.S. EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 83 CANADA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 84 CANADA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 85 CANADA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 86 CANADA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 87 CANADA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 88 CANADA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 89 CANADA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 90 CANADA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 91 CANADA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 92 CANADA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 93 CANADA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 94 CANADA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 95 CANADA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 96 CANADA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 97 CANADA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 98 CANADA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 99 CANADA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 100 CANADA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 101 CANADA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 102 CANADA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 103 CANADA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 104 CANADA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 105 CANADA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 106 CANADA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 107 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 108 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 109 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 110 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 111 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 112 EUROPE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 113 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 114 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 115 EUROPE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 116 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 117 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 118 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 119 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 120 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 121 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 122 EUROPE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 123 EUROPE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 124 EUROPE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 125 EUROPE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 126 EUROPE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 127 EUROPE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 128 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 129 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 130 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 131 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)
TABLE 132 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 133 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 134 GERMANY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 135 GERMANY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 136 GERMANY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 137 GERMANY EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 138 GERMANY EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 139 GERMANY EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 140 GERMANY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 141 GERMANY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 142 GERMANY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 143 GERMANY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 144 GERMANY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 145 GERMANY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 146 GERMANY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 147 GERMANY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 148 GERMANY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 149 GERMANY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 150 GERMANY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 151 GERMANY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 152 GERMANY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 153 GERMANY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 154 GERMANY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 155 GERMANY EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 156 GERMANY EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 157 GERMANY EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 158 FRANCE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 159 FRANCE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 160 FRANCE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 161 FRANCE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 162 FRANCE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 163 FRANCE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 164 FRANCE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 165 FRANCE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 166 FRANCE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 167 FRANCE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 168 FRANCE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 169 FRANCE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 170 FRANCE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 171 FRANCE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 172 FRANCE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 173 FRANCE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 174 FRANCE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 175 FRANCE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 176 FRANCE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 177 FRANCE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 178 FRANCE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 179 FRANCE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 180 FRANCE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 181 FRANCE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 182 U.K. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 183 U.K. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 184 U.K. EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 185 U.K. EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 186 U.K. EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 187 U.K. EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 188 U.K. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 189 U.K. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 190 U.K. EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 191 U.K. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 192 U.K. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 193 U.K. EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 194 U.K. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 195 U.K. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 196 U.K. EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 197 U.K. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 198 U.K. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 199 U.K. EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 200 U.K. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 201 U.K. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 202 U.K. EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 203 U.K. EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 204 U.K. EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 205 U.K. EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 206 ITALY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 207 ITALY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 208 ITALY EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 209 ITALY EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 210 ITALY EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 211 ITALY EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 212 ITALY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 213 ITALY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 214 ITALY EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 215 ITALY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 216 ITALY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 217 ITALY EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 218 ITALY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 219 ITALY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 220 ITALY EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 221 ITALY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 222 ITALY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 223 ITALY EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 224 ITALY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 225 ITALY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 226 ITALY EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 227 ITALY EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 228 ITALY EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 229 ITALY EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 230 SPAIN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 231 SPAIN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 232 SPAIN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 233 SPAIN EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 234 SPAIN EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 235 SPAIN EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 236 SPAIN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 237 SPAIN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 238 SPAIN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 239 SPAIN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 240 SPAIN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 241 SPAIN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 242 SPAIN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 243 SPAIN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 244 SPAIN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 245 SPAIN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 246 SPAIN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 247 SPAIN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 248 SPAIN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 249 SPAIN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 250 SPAIN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 251 SPAIN EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 252 SPAIN EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 253 SPAIN EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 254 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 255 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 256 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 257 APAC EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 258 APAC EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 259 APAC EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 260 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 261 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 262 APAC EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 263 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 264 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 265 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 266 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 267 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 268 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 269 APAC EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 270 APAC EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 271 APAC EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 272 APAC EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 273 APAC EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 274 APAC EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 275 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 276 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 277 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 278 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)
TABLE 279 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 280 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 281 CHINA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 282 CHINA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 283 CHINA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 284 CHINA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 285 CHINA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 286 CHINA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 287 CHINA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 288 CHINA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 289 CHINA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 290 CHINA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 291 CHINA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 292 CHINA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 293 CHINA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 294 CHINA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 295 CHINA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 296 CHINA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 297 CHINA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 298 CHINA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 299 CHINA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 300 CHINA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 301 CHINA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 302 CHINA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 303 CHINA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 304 CHINA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 305 JAPAN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 306 JAPAN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 307 JAPAN EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 308 JAPAN EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 309 JAPAN EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 310 JAPAN EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 311 JAPAN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 312 JAPAN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 313 JAPAN EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 314 JAPAN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 315 JAPAN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 316 JAPAN EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 317 JAPAN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 318 JAPAN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 319 JAPAN EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 320 JAPAN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 321 JAPAN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 322 JAPAN EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 323 JAPAN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 324 JAPAN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 325 JAPAN EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 326 JAPAN EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 327 JAPAN EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 328 JAPAN EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 329 INDIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 330 INDIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 331 INDIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 332 INDIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 333 INDIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 334 INDIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 335 INDIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 336 INDIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 337 INDIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 338 INDIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 339 INDIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 340 INDIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 341 INDIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 342 INDIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 343 INDIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 344 INDIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 345 INDIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 346 INDIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 347 INDIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 348 INDIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 349 INDIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 350 INDIA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 351 INDIA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 352 INDIA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 353 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 354 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 355 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 356 SOUTH KOREA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 357 SOUTH KOREA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 358 SOUTH KOREA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 359 SOUTH KOREA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 360 SOUTH KOREA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 361 SOUTH KOREA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 362 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 363 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 364 SOUTH KOREA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 365 SOUTH KOREA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 366 SOUTH KOREA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 367 SOUTH KOREA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 368 SOUTH KOREA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 369 SOUTH KOREA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 370 SOUTH KOREA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 371 SOUTH KOREA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 372 SOUTH KOREA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 373 SOUTH KOREA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 374 SOUTH KOREA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 375 SOUTH KOREA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 376 SOUTH KOREA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 377 SINGAPORE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 378 SINGAPORE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 379 SINGAPORE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 380 SINGAPORE EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 381 SINGAPORE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 382 SINGAPORE EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 383 SINGAPORE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 384 SINGAPORE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 385 SINGAPORE EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 386 SINGAPORE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 387 SINGAPORE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 388 SINGAPORE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 389 SINGAPORE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 390 SINGAPORE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 391 SINGAPORE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 392 SINGAPORE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 393 SINGAPORE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 394 SINGAPORE EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 395 SINGAPORE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 396 SINGAPORE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 397 SINGAPORE EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 398 SINGAPORE EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 399 SINGAPORE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 400 SINGAPORE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 401 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 402 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 403 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 404 LATAM EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 405 LATAM EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 406 LATAM EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 407 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 408 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 409 LATAM EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 410 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 411 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 412 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 413 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 414 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 415 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 416 LATAM EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 417 LATAM EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 418 LATAM EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 419 LATAM EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 420 LATAM EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 421 LATAM EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 422 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 423 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 424 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 425 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)
TABLE 426 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 427 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 428 BRAZIL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 429 BRAZIL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 430 BRAZIL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 431 BRAZIL EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 432 BRAZIL EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 433 BRAZIL EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 434 BRAZIL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 435 BRAZIL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 436 BRAZIL EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 437 BRAZIL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 438 BRAZIL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 439 BRAZIL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 440 BRAZIL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 441 BRAZIL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 442 BRAZIL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 443 BRAZIL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 444 BRAZIL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 445 BRAZIL EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 446 BRAZIL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 447 BRAZIL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 448 BRAZIL EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 449 BRAZIL EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 450 BRAZIL EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 451 BRAZIL EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 452 MEXICO EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 453 MEXICO EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 454 MEXICO EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 455 MEXICO EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 456 MEXICO EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 457 MEXICO EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 458 MEXICO EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 459 MEXICO EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 460 MEXICO EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 461 MEXICO EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 462 MEXICO EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 463 MEXICO EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 464 MEXICO EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 465 MEXICO EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 466 MEXICO EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 467 MEXICO EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 468 MEXICO EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 469 MEXICO EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 470 MEXICO EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 471 MEXICO EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 472 MEXICO EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 473 MEXICO EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 474 MEXICO EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 475 MEXICO EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 476 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 477 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 478 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 479 MEA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 480 MEA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 481 MEA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 482 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 483 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 484 MEA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 485 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 486 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 487 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 488 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 489 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 490 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 491 MEA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 492 MEA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 493 MEA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 494 MEA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 495 MEA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 496 MEA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 497 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 498 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 499 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 500 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2019–2024)
TABLE 501 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 502 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
TABLE 503 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 504 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 505 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 506 SAUDI ARABIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 507 SAUDI ARABIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 508 SAUDI ARABIA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 509 SAUDI ARABIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 510 SAUDI ARABIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 511 SAUDI ARABIA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 512 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 513 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 514 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 515 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 516 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 517 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 518 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 519 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 520 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 521 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 522 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 523 SAUDI ARABIA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 524 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 525 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 526 SAUDI ARABIA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 527 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2019–2024)
TABLE 528 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 529 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
TABLE 530 SOUTH AFRICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2019–2024)
TABLE 531 SOUTH AFRICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 532 SOUTH AFRICA EMBOLIC AGENTS MARKET, BY TYPE, $M (2025–2030)
TABLE 533 SOUTH AFRICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2019–2024)
TABLE 534 SOUTH AFRICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 535 SOUTH AFRICA EMBOLOTHERAPY SUPPORT DEVICES MARKET, BY TYPE, $M (2025–2030)
TABLE 536 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2019–2024)
TABLE 537 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 538 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
TABLE 539 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2019–2024)
TABLE 540 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 541 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
TABLE 542 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2019–2024)
TABLE 543 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 544 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR CANCER, BY TYPE, $M (2025–2030)
TABLE 545 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2019–2024)
TABLE 546 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 547 SOUTH AFRICA EMBOLOTHERAPY MARKET FOR NEUROLOGICAL DISEASES, BY TYPE, $M (2025–2030)
TABLE 548 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY END USER, $M (2019–2024)
TABLE 549 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 550 SOUTH AFRICA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
TABLE 551 LIST OF OTHER PLAYERS AND THEIR OFFERINGS
TABLE 552 STRYKER CORPORATION – AT A GLANCE
TABLE 553 STRYKER CORPORATION – KEY FINANCIAL SUMMARY
TABLE 554 SIRTEX MEDICAL LIMITED – AT A GLANCE
TABLE 555 SIRTEX MEDICAL LIMITED – KEY FINANCIAL SUMMARY
TABLE 556 MERIT MEDICAL SYSTEMS INC. – AT A GLANCE
TABLE 557 MERIT MEDICAL SYSTEMS INC. – KEY FINANCIAL SUMMARY
TABLE 558 MERIL LIFE SCIENCES PVT. LTD. – AT A GLANCE
TABLE 559 ACANDIS GMBH – AT A GLANCE
TABLE 560 TERUMO CORPORATION – AT A GLANCE
TABLE 561 TERUMO CORPORATION – KEY FINANCIAL SUMMARY
TABLE 562 MEDTRONIC PLC – AT A GLANCE
TABLE 563 MEDTRONIC PLC – KEY FINANCIAL SUMMARY
TABLE 564 KANEKA CORPORATION – AT A GLANCE
TABLE 565 KANEKA CORPORATION – KEY FINANCIAL SUMMARY
TABLE 566 JOHNSON & JOHNSON – AT A GLANCE
TABLE 567 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY
TABLE 568 BOSTON SCIENTIFIC CORPORATION – AT A GLANCE
TABLE 569 BOSTON SCIENTIFIC CORPORATION – KEY FINANCIAL SUMMARY
TABLE 570 ABBOTT LABORATORIES – AT A GLANCE
TABLE 571 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY
TABLE 572 GUERBET – AT A GLANCE
TABLE 573 GUERBET – KEY FINANCIAL SUMMARY
TABLE 574 BALT EXTRUSION SAS – AT A GLANCE
LIST OF FIGURES
FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 6 DATA TRIANGULATION APPROACH
FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)
FIG 8 GLOBAL EMBOLOTHERAPY MARKET SUMMARY
FIG 9 PERCENTAGE INCREASE IN HEALTHCARE EXPENDITURE, BY COUNTRY
FIG 10 BARGAINING POWER OF BUYERS
FIG 11 BARGAINING POWER OF SUPPLIERS
FIG 12 INTENSITY OF RIVALRY
FIG 13 THREAT OF NEW ENTRANTS
FIG 14 THREAT OF SUBSTITUTES
FIG 15 GLOBAL EMBOLOTHERAPY MARKET SNAPSHOT
FIG 16 GLOBAL EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 17 GLOBAL EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 18 GLOBAL EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 19 GLOBAL EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 20 MAJOR WORLDWIDE MARKETS FOR EMBOLOTHERAPY PRODUCTS
FIG 21 NORTH AMERICA EMBOLOTHERAPY MARKET SNAPSHOT
FIG 22 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 23 NORTH AMERICA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 24 NORTH AMERICA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 25 NORTH AMERICA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 26 NORTH AMERICA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
FIG 27 EUROPE EMBOLOTHERAPY MARKET SNAPSHOT
FIG 28 EUROPE EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 29 EUROPE EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 30 EUROPE EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 31 EUROPE EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 32 EUROPE EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
FIG 33 APAC EMBOLOTHERAPY MARKET SNAPSHOT
FIG 34 APAC EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 35 APAC EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 36 APAC EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 37 APAC EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 38 APAC EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
FIG 39 LATAM EMBOLOTHERAPY MARKET SNAPSHOT
FIG 40 LATAM EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 41 LATAM EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 42 LATAM EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 43 LATAM EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 44 LATAM EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
FIG 45 MEA EMBOLOTHERAPY MARKET SNAPSHOT
FIG 46 MEA EMBOLOTHERAPY MARKET, BY PRODUCT, $M (2025–2030)
FIG 47 MEA EMBOLOTHERAPY MARKET, BY PROCEDURE, $M (2025–2030)
FIG 48 MEA EMBOLOTHERAPY MARKET, BY INDICATION, $M (2025–2030)
FIG 49 MEA EMBOLOTHERAPY MARKET, BY END USER, $M (2025–2030)
FIG 50 MEA EMBOLOTHERAPY MARKET, BY COUNTRY, $M (2025–2030)
FIG 51 STRYKER CORPORATION – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2023)
FIG 52 SIRTEX MEDICAL LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)
FIG 53 MERIT MEDICAL SYSTEMS INC. – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2023)
FIG 54 TERUMO CORPORATION – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2023)
FIG 55 MEDTRONIC PLC – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2023)
FIG 56 JOHNSON & JOHNSON – REVENUE SPLIT BY BUSINESS SEGMENT AND GEOGRAPHY (2023)
FIG 57 BOSTON SCIENTIFIC CORPORATION – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2023)
FIG 58 ABBOTT LABORATORIES – REVENUE SPLIT BY BUSINESS AREA AND GEOGRAPHY (2023)
FIG 59 GUERBET – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2023)
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to Analyst
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws